Table 2.

Baseline characteristics of patients treated in LyMa and LyMa-101 trials before and after PSM

SetBefore matching (PS set)After PSM (matching set)Fisher test after PSM, 
P value
NumberLyMa, n = 296LyMa-101, n = 84LyMa, n = 168LyMa-101, n = 84
Sex      
Male 234 (79%) 61 (73%) 121 (72%) 61 (72%) 
Female 62 (21%) 23 (27%) 47 (28%) 23 (27%)  
MIPI risk group      
Low 157 (53%) 46 (55%) 89 (53%) 46 (54%) 
Intermediate 82 (28%) 24 (28%) 50 (30%) 24 (29%) 
High 57 (19%) 14 (17%) 29 (17%) 14 (17%) 
Ann Arbor stage      
II 18 (6%) 2 (3%) 1 (1%) 2 (2%) .2 
III 30 (10%) 6 (7%) 21 (12%) 6 (7%) 
IV 248 (84%) 76 (90%) 146 (87%) 76 (91%) 
B symptoms      
No 209 (71%) 68 (81%) 139 (83%) 68 (81%) .7 
Yes 87 (29%) 16 (19%) 29 (17%) 16 (19%) 
Blastoid variant      
No 261 (88%) 70 (83%) 143 (85%) 70 (83%) .7 
Yes 35 (12%) 14 (17%) 25 (15%) 14 (17%) 
SetBefore matching (PS set)After PSM (matching set)Fisher test after PSM, 
P value
NumberLyMa, n = 296LyMa-101, n = 84LyMa, n = 168LyMa-101, n = 84
Sex      
Male 234 (79%) 61 (73%) 121 (72%) 61 (72%) 
Female 62 (21%) 23 (27%) 47 (28%) 23 (27%)  
MIPI risk group      
Low 157 (53%) 46 (55%) 89 (53%) 46 (54%) 
Intermediate 82 (28%) 24 (28%) 50 (30%) 24 (29%) 
High 57 (19%) 14 (17%) 29 (17%) 14 (17%) 
Ann Arbor stage      
II 18 (6%) 2 (3%) 1 (1%) 2 (2%) .2 
III 30 (10%) 6 (7%) 21 (12%) 6 (7%) 
IV 248 (84%) 76 (90%) 146 (87%) 76 (91%) 
B symptoms      
No 209 (71%) 68 (81%) 139 (83%) 68 (81%) .7 
Yes 87 (29%) 16 (19%) 29 (17%) 16 (19%) 
Blastoid variant      
No 261 (88%) 70 (83%) 143 (85%) 70 (83%) .7 
Yes 35 (12%) 14 (17%) 25 (15%) 14 (17%) 

In this analysis, 296 and 84 patients in the R and O groups, respectively, were matched based on clinical data at inclusion, resulting in 168 and 84 PSM patients in the R and O groups, respectively. Notably, 5 patients (3 in LyMa trial and 2 in LyMa-101 trial) were excluded from this analysis because of missing data (n = 3 with no MIPI group assessment available) or consent withdrawn (n = 2).

Fisher test was done between matched populations.

or Create an Account

Close Modal
Close Modal